FacebookTwitterRedditEmail

The "Good Cancer" Spin

Like Wall Street firms bestowing bonuses weeks after government bailouts, Premarin and Prempro maker Wyeth, recently merged with Pfizer, is unbowed.

Months after a Sen. Charles Grassley-led investigation into its ghostwriting and the unretracted falsified science it planted in medical journals–1,500 documents are found on UCSF’s Drug Industry Document Archive detail the con–the hormone giant is behind new articles in the Journal of Women’s Health and Menopause.

And even after the Women’s Health Initiative (WHI) found in 2002 that hormone therapy (HT) increases breast cancer by 26 per cent, heart attacks by 29 percent, stroke by 41 per cent and doubles the risk of blood clots and dementia, Wyeth still thinks it’s a neat idea.

Women “who are reluctant to take combination hormone therapies because of the publicity after WHI,” writes Michelle P Warren, MD in the journal Menopause (Volume 16, Number 6) as if cancer were a PR problem, might find “improvement in their quality-of-life scores, including that for sleep” by adding another Wyeth drug, bazedoxifene which just happens to be up for FDA approval. The selective estrogen receptor modulator (SERM), says the Wyeth speaker and “advisory board member” according to the journal, would replace the “bad guy” progestin which is causing all the problems in hormone therapy. And replace revenues.

In fact bazedoxifene is such a potential pipeline saver. JoAnn V. Pinkerton, MD, also a Wyeth advisory board member according to Medscape, wrote three articles about it this fall and is “teaching” a Continuing Medical Education (CME) course on it called Controversies in Menopausal Hormone Therapy: Evaluating the Evidence with other pharma-funded doctors on Medscape.

CMEs, required by state boards for doctors to keep their licenses, are often undisguised drug company commercials and also being probed by Sen. Grassley. A CME on Medscape funded by a vaccine maker promises participants on completion of the “educational activity” they will be able to “specify the currently recommended age” for the vaccine. Gentlemen–start prescribing! An osteoporosis CME offered by the Cleveland Clinic Journal of Medicine unabashedly tells participates to “lobby your legislators” to restore reimbursement for bone density testing, a lucrative drug company racket.

Wyeth’s ghostwriting firm DesignWrite introduced seven “corporate-sponsored” CMEs on postmenopausal hormone therapy in 2004–two years after WHI was discredited–in addition to establishing the $12 million Council on Hormone Education at the University of Wisconsin School of Medicine and Public Health which closed in 2008.

Though the 20 million women who quit hormone therapy since 2002 and pulled down breast cancer rates in the process, didn’t do so because it “wasn’t cost effective” (or because of the “publicity” as Warren says) a Wyeth-funded article in the Journal of Women’s Health (Volume 18, Number 10) discovers that hormone therapy is cost effective.

The article compares the financial and quality of life costs of breast cancer, heart attack, stroke and blood clots linked to HT with the hip, vertebral and wrist fractures and colon cancer HT might prevent and finds hormone therapy is cost effective–at least for Wyeth. “Some of the data used in the model were based on assumptions that introduce uncertainty to the results,” the text admits, perhaps referring to the fact that when colon cancer is found in women on HT, it tends to be more advanced. And HT’s osteoporosis benefits require long term use, which is discouraged.

But the cleverest hormone therapy spin is the emerging proposition that a therapy that causes breast cancer and also makes mammograms harder to read, it is now known, is somehow good.

In a Menopause editorial (Volume 16, Number 6) about a breast density study which included women unwilling to discontinue hormone therapy for one to two months to improve readability of their mammograms, we’re told in an ebullient aside “They might have intuitively made the right decision, albeit appearing unwise!” (Exclamation mark the editorials.)

Even though density improved in hormone quitters, their “recall” mammogram rate was not better than non-quitters, says the editorial, implying no immediate benefit to stopping. Of course women who remain on hormone therapy “may face higher mortality from breast cancer in years to come,” the editorial concedes, but an “existing body of knowledge” indicates it is “good prognosis” cancer.

Continuing the good cancer spin is Wyeth-funded doctor Leon Speroff, MD who taught CMEs at the now discredited Council on Hormone Education and who is also a bazedoxifene fan.

In an article in last year’s Menopause, “Postmenopausal Hormone Therapy And The Risk Of Breast Cancer: A Contrary Thought,” (Volume 15, No. 2) Speroff submits that even though “more tumors in hormone users are detected” than in non-hormone users, they are better tumors–“more ductal in situ tumors” and “more node-negative.” Moreover, since the cancers might pre-exist, hormone therapy, by accelerating them, could actually have a “beneficial impact, leading to earlier detection.” A public service–like AIG’s.

MARTHA ROSENBERG can be reached at: martharosenberg@sbcglobal.net

 

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

bernie-the-sandernistas-cover-344x550
February 19, 2020
Ishmael Reed
Social Media: The New Grapevine Telegraph
David Schultz
Bernie Sanders and the Revenge of the Superdelegates
Kenneth Surin
Modi’s India
Chris Floyd
Which Side Are You On?
Linda Pentz Gunter
Hysteria Isn’t Killing Nuclear Power
Dave Lindorff
Truly Remaking Social Security is the Key to Having a Livable Society in the US
ANIS SHIVANI
Bloomberg on Bloomberg: The Selected Sayings of the Much-Awaited Establishment Messiah
Binoy Kampmark
Corporate Occupations: The UN Business “Black List” and Israel’s Settlements
Nozomi Hayase
Assange’s Extradition Case: Critical Moment for the Anti-war Movement
Howard Lisnoff
The Wealth That’s Killing Us Will Save Us: Politics Through the Looking-Glass
Yves Engler
Canada, Get Out of the Lima Group, Core Group and OAS
Nick Licata
The Rule of Law Under Trump
Sam Gordon
A Treatise on Trinities
Nino Pagliccia
Open Letter to Canada’s Prime Minister Justin Trudeau on Lima Group Meeting
John Kendall Hawkins
Just Two Kings Talking
February 18, 2020
John Pilger
Julian Assange Must be Freed, Not Betrayed
Peter Harrison
Religion is a Repeating Chapter in the History of Politics
Norman Solomon
The Escalating Class War Against Bernie Sanders
Conn Hallinan
Irish Elections and Unification
Dean Baker
We Shouldn’t Have to Beg Mark Zuckerberg to Respect Democracy
Sam Pizzigati
A Silicon Valley Life Lesson: Money That ‘Clumps’ Crushes
Arshad Khan
Minority Abuse: A Slice of Life in Modi’s India
Walden Bello
China’s Economy: Powerful But Vulernable
Nicolas J S Davies
Afghan Troops say Taliban are Brothers and War is “Not Really Our Fight.”
Nyla Ali Khan
The BJP is Not India, and Every Indian is Not a Modi-Devotee
Binoy Kampmark
Buying Elections: The Bloomberg Meme Campaign
Jonah Raskin
Here’s Hoping
Evaggelos Vallianatos
Herakles in the Age of Climate Chaos
Bob Topper
The Conscience of a Conservative
John W. Whitehead
We’re All in This Together
Gala Pin
Bodies in Freedom: a Barcelona Story
Laura Flanders
Democracy, Dictatorship and Bloomberg
James Chandler
Among Cruel Children
February 17, 2020
Sheldon Richman
Anti-BDS Laws Violate Our Freedom
John Horning
NEPA is Our National Defense System

Evelyn Leopold
How the UN’s Middle East Peace Plan Was Trounced by Its Own Members
Stephen Cooper
“Just Mercy” and Justice Don’t Exist in Alabama
Patrick Cockburn
Sinn Fein’s Victory is Ireland’s ‘Brexit Moment’ When Left-Out Voters Turn on the Elite
Ralph Nader
“Democratic Socialism” – Bring it on Corporate Socialists!
Phillip Doe
Every Day’s a Holiday for the Oil Business in Colorado
Binoy Kampmark
Fashion Fetishism, Surgical Masks and Coronavirus
Cesar Chelala
The Democrats’ New Chapter
Robert Koehler
The Wall: Separating Democracy From Voters
Peter Cohen
Time to Retire the “He Can’t Beat Trump” Trope
Sr. Kathleen Erickson
Lessons From Ministering on the Border
FacebookTwitterRedditEmail